Telomerase reverse transcriptase (766-780)

Telomerase reverse transcriptase (766-780) is a synthetic peptide fragment corresponding to amino acid residues 766 to 780 of the human telomerase reverse transcriptase (hTERT) protein. As the catalytic subunit of the telomerase enzyme complex, hTERT plays a central role in the maintenance of chromosomal ends by adding telomeric repeats to DNA during replication. The 766-780 region is recognized for its importance in protein-protein interactions, post-translational modifications, and potential immunogenic epitopes, making this peptide fragment highly relevant for studies in telomerase biology, cancer research, and cellular aging. Researchers utilize such defined peptide sequences to dissect the structural and functional domains of hTERT, enabling detailed analysis of its role in cellular processes and regulatory mechanisms.

Epitope mapping: The 766-780 peptide fragment is widely employed to identify and characterize immunogenic regions within hTERT. By serving as a defined epitope, it supports the generation and validation of monoclonal and polyclonal antibodies targeting telomerase. This application is critical for developing immunoassays, such as ELISA or Western blot, aimed at detecting hTERT expression in various biological samples. The high specificity of this peptide sequence allows researchers to distinguish between closely related protein regions, facilitating more accurate immunological studies.

Protein interaction studies: Researchers use this hTERT-derived peptide to investigate protein-protein interactions involving telomerase reverse transcriptase. The 766-780 region is implicated in binding with cellular cofactors, regulatory proteins, or chaperones that modulate telomerase function. By utilizing the peptide in pull-down assays, surface plasmon resonance, or co-immunoprecipitation experiments, scientists can elucidate the molecular partners interacting with this segment, thereby advancing understanding of telomerase regulation and its integration into cellular signaling networks.

Phosphorylation and post-translational modification analysis: The 766-780 segment of hTERT includes sites susceptible to phosphorylation and other modifications, which can influence telomerase activity and localization. Synthetic peptides corresponding to this region are valuable substrates for in vitro kinase assays or mass spectrometry-based studies aimed at mapping modification sites. Analyzing how post-translational modifications affect the peptide's biochemical properties provides insight into the dynamic regulation of telomerase in response to cellular signals or stress.

Peptide-based assay development: The defined sequence of the 766-780 peptide is instrumental in designing competitive binding assays and peptide arrays. Such assays are used to screen for small molecules, peptides, or antibodies that interact with the hTERT C-terminal region, supporting high-throughput drug discovery and inhibitor screening. The synthetic peptide's stability and reproducibility make it a reliable standard for quantitative and comparative studies in telomerase research.

Cellular uptake and functional studies: Incorporation of the 766-780 peptide into cellular models enables exploration of its influence on telomerase activity, localization, and cellular phenotypes. By introducing the peptide into cultured cells, either alone or as part of fusion constructs, researchers can assess its capacity to modulate telomerase-associated pathways or act as a dominant-negative fragment. These studies contribute to a deeper understanding of telomerase's non-canonical functions and its broader impact on genomic stability and cell fate decisions.

1. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

2. TMEM16F and dynamins control expansive plasma membrane reservoirs

3. Tachykinin-related peptides modulate immune-gene expression in the mealworm beetle Tenebrio molitor L

4. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

5. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis